AUSTIN, Texas


,


April 6, 2022


/PRNewswire/ — Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences as follows:

Conference: 21

^st

Annual Needham Virtual Healthcare Conference,

April 11-14, 2022


Presentation Date/Time: Wednesday, April 13 at

9:30 a.m. EDT


Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and CEO

Webcast:

https://wsw.com/webcast/needham117/agle/2213747

To access live and/or archived Investor Conference webcasts, visit the

Events & Presentations

section of the Company’s website. A replay of Company webcasts is archived on the website for 30 days following presentations.

About Aeglea BioTherapeutics


Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. In

December 2021

, Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency. Pegzilarginase has received both Rare Pediatric Disease and Breakthrough Therapy Designations. Aeglea also has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit

.

View original content to download multimedia:

https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-the-needham-virtual-healthcare-conferences-in-april-2022-301518753.html

SOURCE Aeglea BioTherapeutics, Inc.